Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi’s Edoxaban Wins FDA Panel Nod On Approval But Mixed Verdict On Population, Dose

This article was originally published in PharmAsia News

Executive Summary

Cardio-renal committee votes 9-1 for approval of Daiichi’s anticoagulant for stroke risk reduction in patients with nonvalvular atrial fibrillation, but only five panelists said the currently proposed 60 mg dose should be approved for patients with normal renal function given adverse efficacy results in this subpopulation.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts